This patient also had concurrent deletions in CDKN1B and CDKN2B. These alterations are predicted to cause sensitivity to CDK2/425 and/or CDK4/6 inhibitors.26 Regardless of the presence of HR-deficiency–conferring alterations, this patient, who had no residual tumor after surgery, progressed 8.9 months after the last platinum cycle. The gene discussed is CDK2; the disease is neoplasm.